Business Context and Reporting Period
Quoin Pharmaceuticals Ltd. (QNRX) filed a Form 8-K on April 4, 2025, reporting a material modification to the rights of security holders. The company is incorporated in Israel and maintains its principal executive offices in Ashburn, Virginia.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a corporate action regarding share structure.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-20 reverse split of American Depositary Shares (ADSs).
- Ratio Adjustment: The ratio of ADSs to Ordinary Shares changed from 1:1 to 1:20.
- Effective Date: The change is effective at the market open on April 8, 2025.
- Trading Symbol: ADSs will continue to trade on The Nasdaq Capital Market under the symbol "QNRX".
- New CUSIP: The new CUSIP number for the ADS is 74907L409.
Outlook, Risks, and Management Commentary
Objective: The primary goal of the reverse split is to increase the per-share market price to comply with Nasdaq's $1.00 minimum bid price requirement and maintain the company's listing status.
Risks and Contingencies: Management explicitly stated that while the market price per ADS is expected to increase proportionally, the company provides no assurance that this action will result in satisfying or maintaining the Nasdaq minimum bid price requirement.
Shareholder Action: Holders of uncertificated ADSs in the Direct Registration System (DRS) or Depository Trust Company (DTC) require no action; the exchange will occur automatically. Registered holders of certificated ADSs must surrender their certificates to the depositary bank for cancellation to receive new ADSs.
Investor Verification Checklist
- Verify the effective date of the 1-for-20 reverse split (April 8, 2025).
- Confirm the new CUSIP number (74907L409) for trading purposes.
- Check if the post-split share price meets the $1.00 Nasdaq minimum bid requirement.
- Review the company's subsequent filings to confirm continued compliance with Nasdaq listing standards.